Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PepGen Inc. ( (PEPG) ) has issued an announcement.
On September 24, 2025, PepGen Inc. announced positive results from its FREEDOM-DM1 Phase 1 study, demonstrating a 53.7% mean splicing correction in patients with myotonic dystrophy type 1 (DM1) following a single 15 mg/kg dose of PGN-EDODM1. This marks the highest splicing correction reported in DM1 patients, with all participants showing improvement. The treatment was generally well-tolerated, with mild to moderate adverse events. These findings reinforce previous data from lower dose cohorts and suggest potential for reversing molecular defects associated with DM1, which could lead to functional improvements in symptoms like myotonia and muscle weakness. PepGen plans to report further data from its ongoing FREEDOM2-DM1 study in early 2026.
The most recent analyst rating on (PEPG) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.
Spark’s Take on PEPG Stock
According to Spark, TipRanks’ AI Analyst, PEPG is a Underperform.
PepGen Inc.’s overall score reflects significant financial challenges, with limited revenue and continued losses. While technical indicators are mixed, the valuation remains unattractive due to negative earnings. Recent corporate events, including promising trial results and board expansions, offer some positive momentum but are insufficient to offset the financial concerns.
To see Spark’s full report on PEPG stock, click here.
More about PepGen Inc.
PepGen Inc. is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies aimed at transforming the treatment of severe neuromuscular and neurological diseases. The company utilizes its Enhanced Delivery Oligonucleotide (EDO) platform, which leverages cell-penetrating peptides to enhance the uptake and activity of conjugated oligonucleotide therapeutics.
Average Trading Volume: 967,958
Technical Sentiment Signal: Buy
Current Market Cap: $87.25M
For an in-depth examination of PEPG stock, go to TipRanks’ Overview page.